“Progress made in reducing heart attack deaths provides a roadmap to address rising mortality rates from arrythmias, heart failure and hypertensive heart disease” HOFFMAN ESTATES, Ill., July 3, 2025 /PRNewswire/ — Heart health leader OMRON Healthcare today issued an urgent health message…
Rhythm
First Clinical Results from MAGiC Catheter Study Published in the Journal of Interventional Cardiac Electrophysiology
ST. LOUIS, July 01, 2025 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the publication of initial clinical results using the MAGiC catheter in the Journal of Interventional Cardiac Electrophysiology. Titled “First In‑Human Results of the MAGiC Robotic Magnetic Navigation Radiofrequency Ablation Catheter,” the publication is the first peer-reviewed literature supporting the efficacy and safety of Stereotaxis’ MAGiC catheter.
New Evidence Supports the Value of Elutia’s Antibiotic-Eluting Platform for Implantable Devices
— The EluPro BioEnvelope findings demonstrate the bioactive properties and superior healing response compared to synthetic materials for cardiac implantable electronic devices (CIEDs) — GAITHERSBURG, Md., July 01, 2025 (GLOBE NEWSWIRE) — Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced the publication of a new study describing the bioinductive effects of its antibiotic-eluting CIED biologic envelope in the Journal of Functional Biomaterials. Researchers from the Department of Cardiac Sciences at the Cumming School of Medicine found that the biomatrix in EluPro controlled inflammation and supported vascularization, key to a healthy device pocket with less scarring and risk of infection. Formation of a fibrotic capsule and bacterial colonization are known precursors to pocket infection, which can compromise both near-term procedural success and long-term pocket health following CIED implantation. The preclinical study demonstrated that EluPro stimulates early proangiogenic signals and reduced fibrosis over time. “What’s compelling is that we’re seeing not just a signal, but a clear biological effect,” said Dr. Paul W.M. Fedak, a professor and cardiac surgeon-scientist, and Director, Libin Cardiovascular Institute, Cumming School of Medicine, University of Calgary. “The EluPro BioEnvelope initiates early proangiogenic signaling that promotes vascularization and healthier tissue integration — while simultaneously reducing fibrosis over time. This dual regenerative and protective response represents a meaningful step forward in improving outcomes for patients with implantable cardiac devices.” In mechanistic studies, fibroblasts, cells critical for tissue repair and healing, released significantly higher levels of growth and wound healing factors in the biomatrix environment compared to controls (p
EnChannel Medical to Acquire Acutus Medical AcQMap™ Electrophysiology Assets
IRVINE, Calif., July 1, 2025 /PRNewswire/ — EnChannel Medical Ltd., a global leader in cardiac electrophysiology innovation, today announced it has signed a definitive agreement to acquire the AcQMap™ High Resolution Imaging and Mapping platform assets from Acutus Medical Inc. The…
Elutia Wins Dual Honors for Innovation and Product Launches at 2025 Medical Device Network Excellence Awards
Recognition highlights EluPro™ Antibiotic-Eluting BioEnvelope’s impact on device protection for cardiac implantable electronic devices (CIEDs) and neurostimulators
Acarix Applauds New Peer-Reviewed Study Demonstrating Cost-Effectiveness of the CADScor®System in U.S. Emergency Departments
Peer-reviewed research finds CADScor® strategy may reduce costs by up to $15.3M per 10,000 patients while safely ruling out heart disease OKLAHOMA CITY, June 26, 2025 /PRNewswire/ — Acarix, a leader in non-invasive cardiac diagnostics, is pleased to announce the publication of a new…
Volta Medical Announces U.S. Label Expansion for Volta AF-Xplorer™ to Include Pivotal TAILORED-AF Clinical Trial Data
Volta Medical Secures U.S. Label Expansion for Volta AF-Xplorer Artificial Intelligence (AI) decision support system, clinically proven to help physicians treat underserved patients with persistent atrial fibrillation. MARSEILLE, France, June 11, 2025 /PRNewswire/ — Volta Medical, a…
First Commercial Implants of WiSE System for CRT patients
SUNNYVALE, Calif., June 10, 2025 /PRNewswire/ — In a major milestone for heart failure treatment, the first commercial patients in the U.S. have been successfully implanted with the FDA-approved WiSE® System—marking the beginning of a new chapter in leadless left ventricular endocardial…
Corify Care announces AI collaboration with Mayo Clinic to improve cardiac arrhythmia care
MADRID, June 3, 2025 /PRNewswire/ — Corify Care, an AI-driven medical technology company specializing in global cardiac mapping and real-time precision guidance for the treatment of cardiac arrhythmias, announced today it has entered into a know-how agreement with Mayo Clinic. Nearly 60…
OMRON Healthcare Evolves the Blood Pressuring Experience with AI-powered AFib detection
Number one doctor and pharmacist-recommended blood pressure monitor brand introduces blood pressure monitors with OMRON Intellisense™ AFib HOFFMAN ESTATES, Ill., May 21, 2025 /PRNewswire/ — Heralding an evolution of the blood pressure monitoring experience, heart health leader OMRON…